Fisher & Paykel HealthcareASX:FPH +0.13%88 Pretax Margin % is 28.79% as of Mar. 2026, which is 4% above its 10-year median of 27.60. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 91.43% on this metric.
The historical rank and industry rank for Fisher & Paykel Healthcare's Pretax Margin % or its related term are showing as below:
ASX:FPH'
s Pretax Margin % Range Over the Past 10 Years
Min: 13.41 Med: 27.6 Max: 39.31
Current: 27.36
ASX:FPH's Pretax Margin % is ranked better than 91.43% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.61
vs ASX:FPH: 27.36
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Fisher & Paykel Healthcare Pretax Margin % Related Terms
Fisher & Paykel Healthcare Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:FPH vs ISRG, BDX, MDLN: Pretax Margin % Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a Pretax Margin % of 28.79% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 27.60. Over the past decade, Fisher & Paykel Healthcare's Pretax Margin % has ranged from 13.41 to 39.31. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #70 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 8.6%.
Is Fisher & Paykel Healthcare's Pretax Margin % too high?
Fisher & Paykel Healthcare's current Pretax Margin % of 28.79% is near median its 10-year median of 27.60. Over the past 10 years, this metric has ranged from a low of 13.41 to a high of 39.31. The Medical Devices & Instruments industry median Pretax Margin % is 2.61. Fisher & Paykel Healthcare's value of 28.79% is 1003.1% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #70 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Pretax Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #70 out of 817 companies for Pretax Margin %. This places Fisher & Paykel Healthcare in the top 9% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 2.61. Fisher & Paykel Healthcare's value of 28.79% is 1003.1% above this benchmark. Historically, Fisher & Paykel Healthcare's own Pretax Margin % has ranged from 13.41 to 39.31 over the past decade. While the company's 10-year median is 27.60 vs. the industry median of 2.61, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.61, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Pretax Margin % of 28.79% is 1003.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Pretax Margin % is 28.79%, which is near median its own 10-year median of 27.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.31, compared to a current price of A$31.57 — trading 13.1% below its estimated fair value. The current Pretax Margin % is 28.79%, which is near median its 10-year median of 27.60 and 1003.1% above the Medical Devices & Instruments industry median of 2.61. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Pretax Margin % is 28.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$31.57 is trading 13.1% below its estimated GF Value™ of A$36.31.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
Pretax Margin %: 28.79% (near median its 10-year median of 27.60)
GF Value™: A$36.31 vs. price of A$31.57 (13.1% below fair value)
Industry Position: 1003.1% above the Medical Devices & Instruments median (#70 of 817)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
